Categories
Change Password!
Reset Password!
The analysis estimates Baricitinib's patient-reported outcomes (PROs) as monotherapy or combined with Methotrexate (MTX) among RA individuals with no or minimum previous traditional synthetic disease-modifying antirheumatic drugs (DMARDs) and naïve to biological DMARDs.
Disease-modifying anti-rheumatic drugs (DMARDs),
especially Methotrexate (MTX) are the topmost treatment regimen for rheumatoid
arthritis (RA). But, they have been shown to mitigate joint damage and
inflammation. Therefore, RA-BEGIN study demonstrated that Baricitinib alone or
in combination with MTX, showed significant improvement as compared to MTX.
The analysis estimates Baricitinib's patient-reported
outcomes (PROs) as monotherapy or combined with Methotrexate (MTX) among RA
individuals with no or minimum previous traditional synthetic disease-modifying
antirheumatic drugs (DMARDs) and naïve to biological DMARDs.
A total of 159 participants received 4 mg Baricitinib
once daily, 210 obtained MTX administered once weekly and 215 obtained
combination of Baricitinib and MTX. PROs involved EuroQol 5-Dimensions (EQ-5D)
Health State Profile, worst tiredness, patient's assessment of pain, Work
Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA), duration
of morning joint stiffness (MJS), Acute (SF-36), Health Assessment
Questionnaire-Disability Index (HAQ-DI), the Patient’s Global Assessment of
Disease Activity (PtGA), worst joint
pain, Short Form 36 version 2, and
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Logistic
regression models and analysis of covariance (ANCOVA) were performed to assess
the comparisons.
Participants involved in both Baricitinib groups
exhibited greater improvement (p ≤ 0.01) in pain, worst joint pain, fatigue,
HAQ-DI, SF-36 physical component score,
EQ-5D, and PtGA at 24th and 52nd week as compared to the MTX. For the
SF-36 mental component score, participants of both Baricitinib groups presented
statistically notable improvements at the 52nd week as compared to MTX-treated
patients. Further for WPAI-RA, Baricitinib groups showed statistically significant
improvements than MTX at week 24 and Baricitinib + MTX at week 52.
Baricitinib in uniting with MTX or singly, when employed
as initial therapy, appeared in notable improvement than MTX in the various
pre-specified PRO measures.
Arthritis Res Ther. 2017; 19: 208.
Patient-reported outcomes of Baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
Michael Schiff et al.
Comments (0)